| Date | Title | Description |
| 08.09.2022 | 3 takeaways from Johns Hopkins Technology Ventures’ annual report | Johns Hopkins University is offering a by-the-numbers look into its entrepreneurship ecosystem with the recent release of Johns Hopkins Technology Ventures’ (JHTV) annual report.
JHTV works with faculty and students to bring discoveries fro... |
| 16.12.2021 | Johns Hopkins spinout Avidea was acquired by UK company Vaccitech for $40 million | UK biopharmaceutical company Vaccitech has acquired Johns Hopkins spinout Avidea Technologies in a deal valued at $40 million.
Vaccitech developed the technology behind the AstraZeneca COVID-19 vaccine in partnership with Oxford University,... |
| 14.09.2021 | As UK Gov reaches out to tech, investors threaten to ‘pull capital’ over M&A regulator over-reach | U.K. competition regulators are spooking tech investors in the country with an implied threat to clamp down on startup M&A, according to a new survey of the industry.
As the U.K.’s Chancellor of the Exchequer engaged with the tech indus... |
| 05.05.2021 | VACCITECH PLC
Vaccitech Announces Closing of $110.5 Million Initial Public Offering | OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and preven... |
| 04.05.2021 | Vaccitech raises $110.5M in US debut | Vaccitech, the biotech startup behind the technology used to develop the Oxford-AstraZeneca COVID-19 vaccine, has raised $110.5 million in its US IPO. The UK-based company sold 6.5 million shares at a price of $17 each. Vaccitech's shares o... |
| 01.05.2021 | Vaccitech, the biotech startup behind AstraZeneca COVID-19 vaccine developed using an altered form of chimpanzee cold virus, tumbles 20% in Nasdaq IPO debut | Vaccitech is an Oxford, U.K.-based biotech startup developing vaccines and immunotherapies for infectious diseases and cancer, such as hepatitis B, HPV, and prostate cancer. Vaccitech owns the technology used to develop the AstraZeneca COVI... |
| 30.04.2021 | Vaccitech prices shares at $17 for U.S. IPO | By Reuters Staff
1 Min Read
FILE PHOTO: Vials of Oxford/AstraZeneca's COVID-19 vaccine are pictured at a vaccination centre in Bierset, Belgium March 17, 2021. REUTERS/Yves Herman
(Reuters) - Vaccitech Plc, the biotech startup that owns the... |
| 30.04.2021 | Vaccitech prices shares at $17 for U.S. IPO | The British company expects gross proceeds of $110.5 million from the offering of 6.5 mln of its American Depositary Shares (ADSs), representing the same number of ordinary shares.
Vaccitech had announced its plans to go public earlier this... |
| 30.04.2021 | Vaccitech prices shares at $17 for U.S. IPO | April 29 (Reuters) - Vaccitech Plc, the biotech startup that owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca Plc, priced its ordinary shares at $17 each on Thursday ahead of its U.S. initial pu... |
| 26.04.2021 | AstraZeneca : Vaccitech, startup behind AstraZeneca's COVID-19 vaccine, targets $613 mln valuation in U.S. IPO | April 13 (Reuters) - Biotech startup Vaccitech, which owns the technology behind the COVID-19 vaccine developed by AstraZeneca Plc jointly with the Oxford University, said on Monday it was aiming for a valuation of up to $613 million in its... |
| 26.04.2021 | Oxford COVID-19 vaccine tech maker Vaccitech targets $613 million valuation in U.S. IPO | (Reuters) - Biotech startup Vaccitech, which co-invented the COVID-19 vaccine developed by AstraZeneca Plc and Oxford University, said on Monday it was aiming for a valuation of up to $613 million in its U.S. initial public offering.
The co... |
| 26.04.2021 | AstraZeneca : Oxford COVID-19 vaccine tech maker Vaccitech targets $613 million valuation in U.S. IPO | The company, which has development programs for conditions including hepatitis B, prostate cancer and non-small cell lung cancer, has raised $216 million to date from Gilead Sciences, Sequoia Capital China and Oxford Sciences Innovation amo... |
| 26.04.2021 | Oxford COVID-19 vaccine tech maker Vaccitech targets $613 mln valuation in U.S. IPO | April 13 (Reuters) - Biotech startup Vaccitech, which co-invented the COVID-19 vaccine developed by AstraZeneca Plc and Oxford University, said on Monday it was aiming for a valuation of up to $613 million in its U.S. initial public offerin... |
| 26.04.2021 | ASTRAZENECA PLC
AstraZeneca : Oxford COVID-19 vaccine tech maker Vaccitech targets $613 million valuation in U.S. IPO | The company, which has development programs for conditions including hepatitis B, prostate cancer and non-small cell lung cancer, has raised $216 million to date from Gilead Sciences, Sequoia Capital China and Oxford Sciences Innovation amo... |
| 26.04.2021 | Vaccitech Targets $613 Million Valuation in US IPO | Vaccitech plc said on April 26, 2021 it was aiming for a valuation of up to $613 million in its U.S. initial public offering (IPO). The company has raised $216 million to date from Gilead Sciences GILD.O, Sequoia Capital China and Oxford Sc... |
| 22.03.2021 | UK startup that co-invented the AstraZeneca Covid-19 vaccine raises €141.3M; reportedly prepares for IPO | UK-based Vaccitech, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, has raised $168M (approx €1... |
| 19.03.2021 | UK-based Vaccitech bags $168M Series B | Biopharma startup Vaccitech has raised $168 million in a round led by M&G Investment Management. Based in Oxford, the startup develops immunotherapies and vaccines to treat infectious diseases and cancer. The capital will be used to fun... |
| 18.03.2021 | Vaccitech Raises $168M in Series B Financing | Vaccitech Ltd, an Oxford, UK – based clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, raised $168m... |
| 17.03.2021 | Oxford vaccines spinout Vaccitech raises $168M, laying groundwork for an IPO | Vaccitech’s Series B round of funding was led by M&G Investment Management, part of M&G plc, a global investment firm headquartered in London. Other new investors included Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund... |
| 17.03.2021 | Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results | OXFORD, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and preve... |
| 23.10.2020 | BiondVax stock implodes after a big PhIII gamble for its universal flu vaccine fails | After flying high on Wall Street for the last few months of a pandemic, BiondVax’s stock and dreams of getting approval for its universal flu vaccine hit the windshield.
The Jerusalem-based biotech announced on Friday that its ... |
| 19.07.2019 | Seer adds ex-FDA chief Mark McClellan to the board; Hercules Capital makes it official for new CEO Scott Bluestein | Mark McClellan
→ On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its boar... |
| 03.06.2019 | Oxford Startups to Watch: Healthtech, Edutech and More | 3 shares
Share
Tweet
Pin
LinkedIn
Oxford’s outstanding academic reputation and support for innovation have made the city a digital hotspot in recent years. Tech Nation estimates Oxford’s digital turnover at £1.8 billion in 2017, with e... |
| 15.01.2018 | Vaccitech Secures £20M in Series A Funding | Vaccitech, an Oxford University spinout company developing a universal flu vaccine, among other vaccine-related products, secured £20m ($27.1m) in Series A financing.
The round was co-led by new investors GV, Sequoia China, and existing bac... |
| 15.01.2018 | GV co-leads $27.1M Series A in Oxford Uni life sciences spinout Vaccitech | Leaning on its in-house life sciences expertise GV has backed another biotech startup in the UK, co-leading a £20 million ($27.1M) Series A in Oxford University spinout Vaccitech, which is developing a universal flu vaccine.
Sequoia China, ... |
| - | Future Planet Capital acquires Milltrust Agricultural Investments and RT Capital | London-based, but Cayman Islands registered Future Planet Capital has announced the acquisition of Milltrust Agricultural Investments and RT Capital, effectively bringing $130 million more to Future Planet’s table and taking the total asset... |
| - | Oxford vaccines spinout Vaccitech raises $168M, laying groundwork for an IPO | AstraZeneca’s Covid-19 vaccine is currently top of mind amid concerns about what role, if any, it had in reports of blood clots and whether the shots protect against new variants of the novel coronavirus. Meanwhile, the startup that co-inve... |
